Your chance to help
The following treatments for lymphoma will be
considered at the next Pharmaceutical Benefits Advisory Committee (PBAC)
meeting in November for consideration for inclusion on the Pharmaceutical
Benefits Scheme. (PBS)
OBINUTUZUMAB – (Gazyva) for follicular
lymphoma
BRENTUXIMAB VEDOTIN – (Adecetris) for Hodgkin
Lymphoma
IBRUTINIB – for Mantle Cell Lymphoma
ROMIDEPSIN – for PTCL
VORINOSTAT – for CTCL
Patients, family members, health care organisations, clinicians, researchers and other stakeholders are welcome to provide feedback to PBAC via their online portal. Please don’t underestimate the value of your feedback
http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form
The CLOSING date is the 5th of October, 2016. Patients and carers
will have the opportunity to complete the Lymphoma Australia survey for Gazyva,
Adecetris and Ibrutinib after World Lymphoma Day.
